Insulin glargine 300 U/mL safety data in pregnancy

被引：0
|
作者：
Westerbacka, Jukka [1 ]
Duverne, Marielle [1 ]
Grulovic, Natasa [1 ]
Thummisetti, Sreenivas [2 ]
Doder, Zoran [3 ]
机构：
[1] Sanofi, 46 Ave Grande, F-75017 Paris, France
[2] Sanofi, Hyderabad, India
[3] Sanofi, Bridgewater, MA USA
来源：
DIABETES OBESITY & METABOLISM | 2025年 / 27卷 / 05期
关键词：
gestational diabetes; glycaemic control; hypoglycaemia; insulin glargine; pregnancy; GLYCEMIC CONTROL; PERINATAL OUTCOMES; RANDOMIZED-TRIAL; ASPART; WOMEN; PROVIDES; DEGLUDEC; DETEMIR;
D O I：
10.1111/dom.16295
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2322 / 2325
页数：4
相关论文
共 50 条
  • [41] Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?
    Heise, Tim
    Heckermann, Sascha
    DeVries, J. Hans
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2051 - 2056
  • [42] Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
    de Galan, Bastiaan E.
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 2097 - 2106
  • [43] Efficacy and safety of insulin glargine 300 U/mL in people with T2D in China: the INITIATION study
    Chen, L.
    Wan, H.
    Han, J.
    Yang, C.
    Shao, H.
    Li, J.
    Yan, W.
    Zhang, M.
    Li, M.
    Han, Y.
    Kang, L.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [44] Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
    Bolli, Geremia B.
    Cheng, Alice
    Charbonnel, Bernard
    Aroda, Vanita R.
    Westerbacka, Jukka
    Bosnyak, Zsolt
    Boelle-Le Corfec, Emmanuelle
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1588 - 1593
  • [45] In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
    Schiavon, Michele
    Visentin, Roberto
    Giegerich, Clemens
    Sieber, Jochen
    Dalla Man, Chiara
    Cobelli, Claudio
    Klabunde, Thomas
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (08) : 553 - 561
  • [46] Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
    Buscemi, Silvio
    Randazzo, Cristiana
    Buscemi, Carola
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (06) : 1595 - 1596
  • [47] Safety of Insulin Glargine in Pregnancy
    Ansar, Sameer
    Mian, Saadia
    Roth, Steven
    Hebdon, George Matthew
    Aldasouqi, Saleh
    Gossain, Ved V.
    JOURNAL OF DIABETES & METABOLISM, 2013, 4 (02)
  • [48] Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis
    Joshi, Shashank R.
    Singh, Gursharan
    Marwah, Ashwani
    Mittra, Shivani
    Suvarna, Viraj R.
    Athalye, Sandeep N.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1589 - 1606
  • [49] Innovations in Insulin: Insulin Glargine U-300
    Anderson, John E.
    JOURNAL OF FAMILY PRACTICE, 2016, 65 (10): : S23 - S28
  • [50] The effectiveness of insulin glargine 300 U/ml among type 2 diabetes patients: analysis of a real world data
    Cohen, C. Melzer
    Shalev, V.
    Chodick, G.
    DIABETOLOGIA, 2019, 62 : S436 - S437
12345